In July 2013, Optinose licensed exclusive North American rights for the commercialization and further development of ONZETRA® Xsail® (sumatriptan nasal powder) to Avanir Pharmaceuticals. ONZETRA Xsail received FDA approval for the acute treatment of migraines.

Other Partnerships and Technology Licenses

Although focused on development of its own proprietary new treatments, Optinose has allowed use of its technology by a small number of academic researchers, and entered into technology licensing arrangements with carefully selected companies developing their own products that may benefit greatly from this unique type of drug delivery. If your research may benefit from the use of the unique Optinose delivery technology, please call or contact us using the link below.

Please contact us at if your company is interested in exploring partnership opportunities for an innovative, non-oral or non-injected delivery platform for your proprietary CNS, systemic or topical nasal compounds.